The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2007 Release

December 27, 2007 U.S. District Court Decision about Eisai's Legal Action over Aricept ODT® ANDA Filing
December 25, 2007 Eisai Introduces New Aricept® Dose Formulations for Treatment of Severe Alzheimer's Disease in Japan
December 18, 2007 Eisai Enters into In-licensing Agreement with Minophagen Pharmaceutical for Liver Disease/Allergic Disease Agents Stronger Neo-Minophagen® C and Glycyron® Tablets for Allergic Disease
December 10, 2007 Eisai to Acquire MGI PHARMA, INC.
December 6, 2007 Eisai Celebrates Ground-Breaking Ceremony For New Manufacturing and Research Base in India
December 4, 2007 Eisai and BioArctic Neuroscience Enter Exclusive Licensing Agreement with Novel Antibody Treatment for Alzheimer's Disease
November 29, 2007 Eisai Submits NDA Application of KES524 for Obesity Management in Japan
October 30, 2007 Eisai Announces Change in Regulatory Submission Strategy of E2007 for Parkinson's Disease
September 28, 2007 Eisai Announces Establishment of New Pharmaceutical Marketing Subsidiary in Belgium
September 28, 2007 Kissei and Eisai sign a license agreement to develop and commercialize Glufast®, a rapid-acting insulin secretagogue in China
September 25, 2007 Abbott and Eisai submit application for adalimumab, the only fully human monoclonal anti-TNFalpha antibody, to treat psoriasis
September 5, 2007 Eisai Inc. Enters Exclusive Agreement with Salix Pharmaceuticals, Ltd. to Co-promote “COLAZAL®” for the Treatment of Ulcerative Colitis in the U.S. Market
August 24, 2007 Approval of an additional dosage and administration for secondary eradication of Helicobacter pylori for proton pump inhibitors in Japan
August 23, 2007 Aricept® Receives Approval for Additional Efficacy and Dosage For Treatment of Severe Alzheimer's Disease in Japan
August 23, 2007 Sanko Junyaku and Eisai to Co-promote “Picolumi® ucOC”, Diagnostic Agent Introduced by Sanko Junyaku
New Diagnostic Agent Helps Physicians Make Prescribing Choice for Vitamin K2 Medication Therapy for Osteoporosis Patients
August 11, 2007 UK High Court Ordered NICE To Amend A Guidance for Alzheimer's Disease
August 10, 2007 UK High Court Ruled NICE Guidance for Alzheimer's Disease Discriminatory
July 31, 2007 Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
July 27, 2007 Eisai Co-promotes “PyloriTek® Test Kit”, H. Pylori Infection Diagnostic Kit Launched by Sanko Junyaku
July 27, 2007 Eisai Enters into In-licensing Agreement with Sepracor for Eszopiclone Insomnia Treatment
July 17, 2007 New Individually-Wrapped Tablets Introduced to Selbelle®:
Stomach Medication that Protects Gastric Mucosa from Stomach Acid Now Available in Easy-to-Carry Package
July 11, 2007 Eisai Launches “Nitorol® Injection 5 mg Syringe” and “Nitorol® Continuous Intravenous Infusion 25 mg Syringe”, First Nitric Acid Syringe Formulations Approved in Japan
July 9, 2007 Notice on Details of Stock Options (New Share Acquisition Rights) to be Allocated
June 26, 2007 Tambocor® (Antiarrthymic Treatment) Received Approval for Paroxysmal Atrial Fibrillation/Flutter
June 22, 2007 Notice on Allocation of Stock Options (Stock Acquisition Rights)
June 16, 2007 Inovelon® launched in Germany
June 15, 2007 A ONCE-WEEKLY ANTIOSTEOPOROTIC AGENT “ACTONEL® 17.5 mg TABLETS” IS LAUNCHED.
June 12, 2007 Kissei and Eisai sign a license agreement to develop and commercialize Glufast®, a rapid-acting insulin secretagogue in 10 ASEAN countries
May 15, 2007 Eisai Signs Exclusive Agreement to Commercialize NeuroBloc® for Europe
May 15, 2007 Eisai Submits Application for Gastroprokinetic Agent Gasmotin® in Thailand
May 15, 2007 Notice on New Stock Issuance in the Form of Stock Options
May 15, 2007 Basic Principle and Policies concerning Reduction of Minimum Trading Lots for Shares
May 12, 2007 EISAI OBTAINS FAVORABLE RULING IN ACIPHEX® PATENT INFRINGEMENT LAWSUIT AGAINST TEVA PHARMACEUTICALS AND DR. REDDY'S LABORATORIES
May 7, 2007 Eisai Introduces “Chocola BB® Light 2” Vitamin B2 Drink
A New Drink with Enhanced Formula and Reduced Calories
May 7, 2007 FDA Approves FRAGMIN®, an Injectable Anti-Clotting Agent, for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
April 26, 2007 Eisai Announces Complete Subsidiarization of Sanko Junyaku
April 18, 2007 A ONCE-WEEKLY FORMULATION OF RISEDRONATE SODIUM HYDRATE, AN ANTIOSTEOPOROTIC AGENT, WAS APPROVED.
April 17, 2007 Eisai Announces Completion of Acquisition of Morphotek
April 13, 2007 Eisai Withdraw Application for Additional Indication of Aricept® for Treatment of Severe Alzheimer's Disease in Europe
March 26, 2007 Asahi Kasei Pharma Corporation and Eisai Co., Ltd.
Signed License Agreement for Vasodilator Eril® in Korea
March 22, 2007 EISAI TO ACQUIRE MORPHOTEK
Eisai's Dramatic Leap towards Biologic Therapeutics Evidenced by the Acquisition
March 5, 2007 Eisai Establishes New Manufacturing Subsidiary in United Kingdom
March 1, 2007 Eisai and Abbott Announce Amendment to Agreement for the Co-promotion of Rheumatoid Arthritis Drug HUMIRA® in Taiwan and Korea
February 2, 2007 Notice Regarding Revision of Year End Dividend Forecast For Fiscal Year Period (95th Company Fiscal Period) Ending March 2007
January 30, 2007 Proton Pump Inhibitor Pariet® Tablets 10mg Receives Approval in Japan for Helicobacter Pylori Eradication
January 22, 2007 Inovelon® recieves Marketing Authorization Approval from European Commission

Back to Top